Oncolytics Biotech Inc T.ONC

Biotech buyouts.

[fox7mf]

When looking at Immunomedics 2020 buyout by Gilead for $21b, that price represents a 108% premium to the previous days closing price of the stock. If Onc were to be purchased today for $8b, that represents somewhere close to an 11000% premium over our current stock price. Should we be tempering our expectations? I'm confident, but I just wonder if BP will go for something like this. Excuse me if my numbers are off.

[Lesalpes29]

It's easy... multiply the actual matket cap by 100! A SP just over 100$ ... a bit ridiculous at the moment! But things can change fast.

[westcoast1000]

I share your concerns, fox7mf. I do not know what to think here.

[jimsenior]

There does seem to be a problem with the low share price given the promise of pela. I do not have an explanation but I suspect the ATM is being used. I think management has said they are striving to get the best deal for shareholders and if that involves the ATM, I get that and if I add a few shares I would in essence be buying directly from the company. Before I add, I would like to know that

[Noteable]

Perhaps it would be useful for posters on this message board better understand the fundamentally different responsibilities between a company's board of directors and its management which I have tried to briefly summarize below. Directors and officers play fundamentally different roles within a corporation. Under Delaware law, “[t]he business and affairs of every corporation . . . shall

[Noteable]

The board’s principal responsibility is to protect and enhance stockholder value. Mergers and acquisitions offer one way that stockholder value can be increased.  On the sell-side, particular where the board is considering the sale of the company, the board should assess the timing and adopt a process. The board should stay actively involved throughout the process, overseeing management and

[Capitalista]

Finally, we have some measured discussion on this board that is neither over-the-top praising nor damning.  There's hope for us yet (unlike the Yahoo board, which seems to have degraded permanently into an ad hominem pig wallow).  Some good points brought up here in the last two days; I need to do some research and hope to have something salient to contribute in a day or two. 

[Noteable]

The Yahoo message board is a "troll factory" run by a hedge fund with the intent of keeping the share price of ONCY low and potential stockholders away. And these developments may be related to the above: October 07, 2022 - Replimune secures US$200 Million in a non-dilutive financing loan facility to pursue the anti-PD-1 failed melanoma indication in which AMGEN's IT.OV Imlygic and

[jimsenior]

Page 38 of the August Presentation states  - Maintain rights in North America in part or in whole -. This is the stated aim of the company. So presumably those resonsible are working wth that statement. Said statement is presumptuous in the extreme in my opinion, but there is nothing I can do about that, and one can only hope they see that they are not entitled to said rights given their

[Noteable]

" Maintain rights in North America in part or in whole " - Not in a buyout 

[jimsenior]

to Noteable, let me preface this by saying I do like reading your posts. Chacun a son gout. Yes. Not in a buyout. But their best foot forward is we want at least Canada, and that  want complicates matters. Perhaps this is done in biotech; surely Pharma knows how to handle this sort of thing. They should just pass it on. You did remind me of something I had been thinking about a while back

[Noteable]

Adlai Nortye's "exclusive" licensing agreement for China, Hong Kong, Macau, Singapore, South Korea and Taiwan was in exchange for an up-front payment on signing, followed by a significant milestone payment on the inititiation of a Phase III pelareorep study, and then lower mid-level double digit royalty payments on gross revenues stemming from product approval and commercialization.

[Lesalpes29]

ATM ATM action again? A real shame if it's the case.

[Noteable]

There is no proof of ATM activity. And jimsenior's speculation is has no validity.

[Noteable]

Just the same hedge fund activity that as I suggested in an earlier post and those posters on this message board working in concert with them

[jimsenior]

Not me. Just asking questions. A few of us would like to know what is behind the low share price versus the promise of pela. Recent form says today's drop will pop back within 2 days hopefully. I am still planning to add a few, just not sure when.

[Noteable]

I've answered your questions. And proposed the reasons why.

[Lesalpes29]

If past results can't move the SP higher maybe the next will do it. But actually the SP is not suggesting a buyout over 1B. But we can dream!

[fox7mf]

Could AN not going fwd with Pela reflect that they've been told by Oncy and their prospective acquiring company that they aren't going to have the chance? Could Oncy be tidying up things, as perhaps a deal in principle has been reached? Just thinking out loud.

[westcoast1000]

jimsenior, IIRC, Matt was the last of the "founders" who had some kind of royalty agreement on sales. All the other founders dropped off (e.g., Brad). Whether that agreement still exists I do not know. If it did, and he were not compensated in a purchase, he could have an incentive to avoid a change of ownership. On the other hand, he may have some kind of change of ownership

[jimsenior]

Yes. Thank you. Royalty was the word I was looking for. I heard that somehow the MC royalty was dealt with; but who knows. I have been looking at the AN agreement, and don't get it much more now than I did in 2017. I think we can say AN has not started a Phase 3 mBC, so there is that. I am thinking that matters have changed so much since the inception of that deal that AN may in fact not be

[Noteable]

Matt Coffey surrendered any "founder's rights to future payments. ONCY's BOD and management's incentives are fully tied to the options that they've been granted. Consequently, the acquisition of ONCY by one of the Big Pharma players, serves as management's greatest motivation for moving ONCY towards a sale of the company for the best price.

[jimsenior]

Thank you for explaining page 38. It is strange that AN appears not to be going forward with pela. Their own words were not particularly encouraging. If they do not go forward I wonder what happens to the deal with ONC. Can AN sell the rights or do they revert back to ONC.

[Noteable]

I suggest you re-read the panel displayed on page 38 and pay partiular attention to the panel subject matter headline. What you see is in this panely is the objective of a business development strategy anchored by partnerships with large pharmaceutical companies. This panel describes the objective in a joint development and commercialization partnership. Not a Big Pharma buyout !  The reason